In addition to hematological malignancies, recently, increasing evidences demonstrate that TET2 is implicated in progression of solid tumors, including prostate cancer, gastric cancer, epithelial ovarian cancer, melanoma and breast cancer7,8,16–18. This evidence concerns the gene TET2 and Familial prostate cancer.